Clinical trial · Interventional
Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiofrequency (RF) could be technically feasible and effective in the treatment of lymph node metastases of differentiated thyroid cancer. It could constitute a minimally invasive and feasible therapeutic alternative in ambulatory, allowing a reduction of the tumoral volume sufficient to limit the symptoms even to induce a tumor remission, a normalization of the tumoral markers and a better quality of life. The aim of this study is to evaluate the anti-tumor echographic efficacy at 12 months of radiofrequency on lymph node (LN) metastasis of thyroid cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Differentiated Thyroid Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiofrequency (RF star electrode electrode_Fixed) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiofrequency
- interventionNames
- Device: Radiofrequency (RF star electrode electrode_Fixed)
Primary outcomes (1)
- measure
- Treatment response.
- timeFrame
- 12 months
- description
- Treatment success wil; be defined on the following three criteria that should be all fulfilled * Loss of metastatic aspect on ultrasonography * LN decreased volume at least 50% * no vascularization in Doppler
Secondary outcomes (14)
- measure
- Percentage of patients with non-suspicious cyto-punction of treated LN at 6 months after RF
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients over age of 18 years * with differentiated thyroid cancer (papillary, follicular) histologically confirmed, and absence of anaplastic component * Previous treatment by total thyroidectomy and cervical lymph node dissection. * Previous treatment by at least 1 therapeutic radioactive iodine (minimum activity 740MBq) * Persistence on cervical ultrasound of at least 1 cervical metastatic lymph node, visible at ultrasound, small diameter between ≥10 mm and ≤30mm, volume maximum 20ml, spotted on a picture, and confirmed by cyto-punction * Signed informed consent Exclusion Criteria: * Location of LN metastasis with significant risk of local complication (nervous, vascular) according baseline ultrasound assessment * Patient carrier of a pacemaker or a defibrillator * Congenital or acquired hemostasis abnormality, anticoagulant therapy or double platelet antiaggregatory (aspirin and clopidogrel) * Hypersensitivity to local anesthetic * Poor general condition (performance status Eastern Cooperative Oncology Group (ECOG) \> 1) * Survival estimated less than 12 months * Patient who can't follow the instructions of RF therapy or who can't be followed during 2 years in order to meet the objectives of the study * Non affiliation to a social security * Pregnant or breast feeding women at the time of RF * Beta hormone chorionic gonadotrope (HCG) positive test (pregnancy) before RF therapy * Baseline cervical ultrasound, by expert operator trained to RF, not fulfilling feasibility criteria for RF realisation because of the location of LN metastasis or the way to reach it * Controlateral recurrent palsy on nasofibroscopy
References
Publications (0)
Data not yet available